BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Infinitopes Raises £12.8M to Expand Precision Immunomics™ for Five Additional Cancers

- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen disco...

May 01, 2024 | News

FDA Approves Ractigen Therapeutics' IND for Groundbreaking Bladder Cancer Therapy

Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration...

April 29, 2024 | News

Hyundai Bioscience Targets p53 Gene Mutations with Novel Niclosamide-Based Cancer Therapy

The only solution for intractable cancer caused by mutations in the p53 gene Planning clinical trials targeting cancer patients with no available treatm...

April 26, 2024 | News

Dizal to Present New Data on Sunvozertinib for Lung Cancer at ASCO 2024

Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases...

April 25, 2024 | News

Hanmi Pharmaceutical Partners with MSD to Advance Immuno-Oncology Drug BH3120 in New Clinical Trial

Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesit...

April 24, 2024 | News

OSR Holdings and SillaJen Forge Strategic Partnership to Enhance Immuno-Oncology Drug Development

OSR Holdings, a global healthcare holding company, announced that it has signed a memorandum of understanding (MOU) with SillaJen, a Kosdaq-listed biotech ...

April 23, 2024 | News

Hyundai Bioscience Launches Clinical Trials for Innovative Niclosamide-Based Cancer Drug

Clinical trials of Niclosamide-based oral metabolic anticancer drug to commence for patients with difficult-to-treat cancers such as triple-negative...

April 23, 2024 | News

GenFleet Therapeutics Secures FDA Approval for Pioneering Phase III KRAS G12C Inhibitor Trial in Colorectal Cancer

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Adm...

April 22, 2024 | News

Serum Institute of India and Univercells Unite to Make Personalized Cancer Treatments Widely Available

Serum Institute of India (SII), the world’s largest vaccine manufacturer, has joined forces with Univercells, a Belgian biotech innovator,...

April 12, 2024 | News

Transcenta and Agilent Collaborate on Companion Diagnostic for Advanced Gastric Cancer Trial

Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...

April 09, 2024 | News

Cure Brain Cancer Foundation Launches Pioneering $575,000 Fellowship to Support Emerging Leaders in Brain Cancer Research

Cure Brain Cancer Foundation proudly unveiled the launch of its groundbreaking 5-Year Guardian Trust Early Career Fellowship, valued at $575,000. The...

April 08, 2024 | News

Dizal's Sunvozertinib Secures FDA Breakthrough Therapy Designation for First-Line EGFR Mutated NSCLC Treatment

Dizal announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the firs...

April 08, 2024 | News

Ractigen Therapeutics Launches Pioneering Phase I Clinical Trial for Bladder Cancer with First Patient Dosed in Collaboration with GenesisCare

Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone with the first patient dosed in its First-in-huma...

April 04, 2024 | News

Bridge Biotherapeutics Partners with Emory University to Advance Lung Cancer Treatment

Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announ...

April 01, 2024 | News

Stay Connected